KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Vir Biotechnology (VIR) Equity Average (2018 - 2025)

Vir Biotechnology's Equity Average history spans 8 years, with the latest figure at $780.7 million for Q4 2025.

  • On a quarterly basis, Equity Average fell 34.7% to $780.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $780.7 million, a 34.7% decrease, with the full-year FY2025 number at $957.8 million, down 30.1% from a year prior.
  • Equity Average hit $780.7 million in Q4 2025 for Vir Biotechnology, down from $871.8 million in the prior quarter.
  • Over the last five years, Equity Average for VIR hit a ceiling of $2.1 billion in Q4 2022 and a floor of $683.9 million in Q1 2021.
  • Historically, Equity Average has averaged $1.4 billion across 5 years, with a median of $1.4 billion in 2024.
  • Biggest five-year swings in Equity Average: surged 184.74% in 2022 and later crashed 34.81% in 2025.
  • Tracing VIR's Equity Average over 5 years: stood at $1.2 billion in 2021, then skyrocketed by 83.17% to $2.1 billion in 2022, then decreased by 22.77% to $1.6 billion in 2023, then fell by 26.77% to $1.2 billion in 2024, then plummeted by 34.7% to $780.7 million in 2025.
  • Business Quant data shows Equity Average for VIR at $780.7 million in Q4 2025, $871.8 million in Q3 2025, and $995.6 million in Q2 2025.